Bayer Agrees On Social Dialogue
At its European Forum, a formal agreement was signed by Bayer staff representatives and management on social dialogue. Chairman Manfred Schneider said he was convinced "that we will one day be a single European company in which we as representatives of the employees and management of Bayer AG will continue the tradition of amicable and constructive cooperation."
Paul Laux, chairman of Bayer's joint and group works council, was elected chairman of the European Forum.
He stressed that the European Forum was the first clearly defined platform for an exchange of information in the Bayer group and would mean permanent cross-border dialogue could be established between the corporate management and representatives of the workforce.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze